This update is based on the results from the June 2022 ATHENA-MONO2 phase III multinational, double-blind, randomized controlled trial (RCT), which showed a significant improvement in progression-free survival (PFS) in patients with stage III-IV epithelial ovarian cancer (EOC) who are in complete or partial response to first-line platinum-based chemotherapy.

An 18-year-old man comes to you for a sports physical. He is asymptomatic, with no limitation in his exercise capacity. He has a history of exercise-induced bronchospasm for which he takes a budesonide-formoterol inhaler. He does not smoke, drink alcohol, or use any drugs. There is no family history of cardiac disease or sudden death. What’s the next appropriate test?

Because this GLP-1 agonist is known to reduce food intake, physicians have been prescribing tirzepatide off-label for weight loss for years. But unlike other drugs in its class, tirzepatide targets GLP-1 and GIP receptors.

In a study involving 212 adults with symptomatic knee osteoarthritis, an unsupervised online yoga program delivered via prerecorded videos over 12 weeks netted improved physical function vs. the control group. At 12 weeks, knee stiffness, quality of life, and arthritis self-efficacy improved more with yoga than the control intervention. Benefits were not maintained at 24 weeks. Adverse events were minor.

On September 20, 2022, Alzheon Inc. announced promising results from its phase 2 trial of oral ALZ-801 (valiltramiprosate) in patients with early AD. The drug decreased p-tau181 levels, reduced brain atrophy, and improved cognitive skills in the trial.

In this interview with Dr. Wendy Marsh, director of the Bipolar Disorders and Depression Specialty Clinics at the University of Massachusetts Chan Medical School, she discusses how treatment can better address quality-of-life issues for individuals with bipolar depression.